The effect of plasma level of 5, 5-dimethyl-2, 4-oxazolidinedione (DMO) and of inhibitors of aqueous secretion on the distribution of DMO in intraocular fluids has been studied. Plasma levels of DMO from 35 to 60 mg./lOO ml. were required to obtain an appreciable excess of DMO in posterior and anterior aqueous humors compared with plasma. At plasma levels below 20 mg./lOO ml. the concentration ...

1. Hepatic intracellular pH (pH,) was measured in intact rats by distribution of 5,5dimethyloxazolidine-2,4-dione (DMO), using [14C]DM0 and a range of doses of unlabelled DMO, previously neutralized with sodium hydroxide. 2. Mean calculated pHi fell from 7-27 to 7-17 as the dose of added unlabelled DMO was increased from zero to 0.19 mmol/kg (25 mg/kg) and thereafter remained constant up to and...

BACKGROUND Olanzapine (OLZ) is one of the most prescribed atypical antipsychotic drugs but its use is associated with unfavorable metabolic abnormalities. N-desmethyl-olanzapine (DMO), one of the OLZ metabolites by CYP1A2, has been reported to have a normalizing action on metabolic abnormalities, but this remains unclear. Our aim was to explore the correlation between the concentrations of OLZ ...

Wave-equation dip moveout (DMO) addresses the DMO amplitude problem of finding an algorithm which faithfully preserves angular reflectivity while processing data to zero offset. Only three fundamentally different theoretical approaches to the DMO amplitude problem have been proposed: (1) mathematical decomposition of a prestack migration operator; (2) intuitively accounting for specific amplitu...

The effect of ammonium chloride (systemic acidosis) and probenecid on the distribution of DMO in intraocular and cerebrospinal fluids has been studied. These drugs increased the level of DMO in intraocular fluids so that DMO was found in excess of plasma levels at plasma levels which normally result in a deficit of DMO in intraocular fluids. Their action seemed to be explained in part by a bloc...

Dynamic optimization and multi-objective optimization have separately gained increasing attention from the research community during the last decade. However, few studies have been reported on dynamic multi-objective optimization (dMO) and scarce effective dMO methods have been proposed. In this paper, we fulfill these gabs by developing new dMO test problems and new effective dMO algorithm. In...

PURPOSE To determine the relationship between retinal ischaemia and the presence of macular oedema (DMO) in patients with diabetic retinopathy (DR) using ultra-widefield fluorescein angiography (UWFA) imaging. METHODS A retrospective review of 122 eyes of 70 treatment-naïve diabetic patients who underwent diagnostic UWFA using the Optos 200Tx imaging system. Two independent, masked graders qu...

09.00-10..30 am Keynote Speech 1 Knowledge Discovery and Management in Life Sciences : Impacts and Challenges Fazel Famili 10.30 11.00 am Tea break 11.00 12.00 am Plenary Address 1 The Application of Primitive Heuristics to Constraint Satisfaction for Complex Real World Optimisation Paul McMullan 12.00 12.30 pm DMO’09 Opening ceremony Announcement of DMO’10 Launch of DMO’10 website 12.30 02.00 ...

Diabetic macular oedema (DMO) is a major cause of blindness that has an increasing prevalence associated with the general population in diabetes worldwide. In DMO, increased expression of factors including vascular endothelial growth factor (VEGF) disrupts the blood– retina barrier causing leakage and accumulation of extracellular fluid in the macula with resultant loss of vision. Focal and gri...

The management of diabetic macular oedema is changing. The therapeutic armamentarium for diabetic macular oedema (DMO) includes a new group of drugs that inhibit vascular endothelial growth factor (VEGF). These anti-VEGF agents are already being used widely in DMO in clinical practice despite that several phase III trials on these drugs are still underway. There are no established protocols on ...